Nanion And Axion Biosystems Announce Strategic Distribution Partnership In Europe And China
Munich, Germany, June 17, 2014; Nanion Technologies, a leading provider of automated patch clamp platforms, and Axion Biosystems, originator of the first high throughput microelectrode array system, today announce a distribution partnership in Europe and China. Nanion will immediately carry Axion’s MEA-products, supporting a broad range of biomedical applications.
Axion Biosystems provides state-of-the-art, high resolution, MEA based instruments for experiments ranging from basic cellular electrophysiology to high throughput screening (HTS). Axion’s MEA systems represent the next generation in multielectrode array technology, providing unprecedented access to native cellular electrical signaling and connectivity. To meet the growing demand for “disease in a dish” assays and functional safety screening, Axion and Nanion today announced a strategic distribution partnership for the European and Chinese markets. Further strengthening and complementing the Nanion product portfolio, Nanion will distribute, service, and support the Axion single-well MEA system, the Muse, and the Maestro, a multiwell MEA system with HTS capabilities.
Dr. Niels Fertig, CEO and founder of Nanion Technologies, says: “We are extremely impressed by Axion’s MEA-systems because of their broad scope of applications, ranging from in-depth, highly resolved cellular network behavior to high throughput drug screening. We think that Axions’s products provide an excellent complement to our automated patch clamp screening and impedance-based systems, and see great potential for applications including phenotype screening, stem cells as tools for phenotypic disease models, and of course, safety, neuro- and cardiotoxicity testing. Additionally, the partnership with Axion will further strengthen us as the one-stop-shop for proficient tools for electrophysiology drug research, screening and intersecting areas.”
Tom O’Brien, CEO of Axion Biosystems, continues: “Nanion is a great match for Axion, since we share the same background and philosophy, ultimately manifested in innovative products. As companies, we both have a solid research- and application-driven focus, as well as a deep understanding and broad expertise in science and technical development. These characteristics are combined with a vision to push the boundaries toward HTS-compatible products. We were attracted to Nanion’s strong track record of growth, and their excellent reputation for customer service and product reliability. We are excited about this partnership and have great confidence that Nanion will be very successful as our sales and distribution partner for the European and Chinese markets.”
Nanion Technologies and Axion Biosystems will be displaying their products together at the MEA-meeting in Reutlingen, Germany, July 1-4, 2014, and at the FENS 2014 meeting in Milan, Italy, July 4-7, 2014.
About Nanion Technologies:
Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established four generations of highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery. Nanion also carries the product lines the CardioExcyte 96, for cardiac safety screening, and the SURFE2R N96, a device for parallel membrane transporter protein recordings. In 2013, Nanion launched a high quality, fully HTS-compatible, automated patch clamp platform, the SyncroPatch 384/768PE, capable of over 20,000 data points per day.
Contact Nanion Technologies:
Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web: www.nanion.de Press contacts: Cecilia Farre, Marketing Director, Phone: +49 89 2189 97973, Email: info@nanion.de
About Axion Biosystems
Axion Biosystems is a life science company focused on solving problems related to human heart and brain activity. Axion tackles these problems by integrating its core technologies – proprietary electronics and microfabrication methods – with biology. This capability has led The Company to initiate the development of products for three different markets – life science instrumentation, medical diagnostics, and implantable stimulation devices.
Contact Axion Biosystems:
Jim Filippini, Director, Global Sales and Marketing, Phone 404-477-2557, Email: info@axionbio.com
Tom O’Brien, CEO, Phone 404-477-2557, Email: info@axionbio.com, Web: www.axionbio.com
Help employers find you! Check out all the jobs and post your resume.